|7th March 2016
In our previous article, we talked about how to mature your organisation’s approach to content strategy. We covered off three key things you can do to move your company forward in 2016. However, not all organisations are in a position to look at maturity – for some, there’s still a pressing question that needs answering: Why does content need a strategy?
In this article, Content Marketing Manager Liz Inskip and guest blogger Adwoa Baah explain how having a documented strategy for content creation, distribution, management, and governance will empower your brand teams and create organisational efficiencies.
A documented strategy for content creation ensures that all content serves a strategic purpose, and is in line with business objectives, as well as customer needs. When content is brought into the strategic process at the beginning, it can shape thinking and drive the overall brand strategy.
For example, some of our clients have the problem of having too much content and no content owners. There isn’t a documented strategy in place for content creation, so new content is constantly being created to meet brand teams’ needs. This tends to mean that there is a proliferation of content, but no strategic guidance around how that content should be created or understanding of how each piece of content will meet business objectives and customer needs. In these cases, a documented strategy has empowered the brand teams to create less content, but the content that was created was purposeful and served a strategic purpose.
|9th July 2019
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking CAR-T therapy for the first patient in Europe, and how the centre of excellence has adapted to make precision medicine a reality
|20th June 2019
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives his side of the story and explains how industry can help oncologists treat more patients with targeted therapies.